Systematic interaction of plasma albumin with the efficacy of chemotherapeutic drugs

Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188655. doi: 10.1016/j.bbcan.2021.188655. Epub 2021 Nov 12.

Abstract

Albumin, as the most abundant plasma protein, plays an integral role in the transport of a variety of exogenous and endogenous ligands in the bloodstream and extravascular spaces. For exogenous drugs, especially chemotherapeutic drugs, binding to and being delivered by albumin can significantly affect their efficacy. Meanwhile, albumin can also bind to many endogenous ligands, such as fatty acids, with important physiological significance that can affect tumor proliferation and metabolism. In this review, we summarize how albumin with unique properties affects chemotherapeutic drugs efficacy from the aspects of drug outcome in blood, toxicity, tumor accumulation and direct or indirect interactions with fatty acids, plus application of albumin-based carriers for anti-tumor drug delivery.

Keywords: Albumin; Chemotherapeutic drugs; Drug carrier; Drug efficacy; Fatty acids; Tumor accumulation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Fatty Acids / metabolism
  • Humans
  • Ligands
  • Neoplasms* / drug therapy
  • Protein Binding
  • Serum Albumin / chemistry
  • Serum Albumin / metabolism

Substances

  • Antineoplastic Agents
  • Fatty Acids
  • Ligands
  • Serum Albumin